Effect of 5‐HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat
Open Access
- 1 February 1990
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 99 (2) , 227-232
- https://doi.org/10.1111/j.1476-5381.1990.tb14685.x
Abstract
The effects of 5‐hydroxytryptamine3 (5‐HT3) receptor antagonists on the behavioural hyperactivity response which results from injection of the neurokinin receptor agonist [pGlu5, MePhe8, Sar9]‐substance P (5–11) (DiMe‐C7) into the ventral tegmental area (VTA) of the rat midbrain have been determined. Subcutaneous administration of ondansetron (GR38032) (0.001–0.3 mg kg−1), GR65630 (0.01 mg kg−1), ICS 205–930 (0.1 mg kg−1) and MDL 72222 (0.1 mg kg−1), inhibited the DiMe‐C7‐induced hyperactivity response. The effects of ondansetron on DiMe‐C7‐induced changes in dopamine and 5‐HT metabolism in discrete areas of rat forebrain were studied in order to investigate further the possible mechanism of action of 5‐HT3 antagonists in modifying mesolimbic dopaminergic systems. Intra‐VTA administration of DiMe‐C7 increased levels of dihydroxyphenylacetic acid (DOPAC) in the nucleus accumbens, olfactory tubercules and right amygdala, indicating increased mesolimbic dopamine metabolism. DOPAC levels were not significantly increased in the frontal cortex, left amygdala or striatum. Dopamine levels were not altered in any of these brain areas. DiMe‐C7 also increased 5‐hydroxyindoleacetic acid (5‐HIAA) levels in the amygdala but this was only statistically significant in the right amygdala. 5‐HT levels were not changed significantly by DiMe‐C7 treatment. In control rats, pretreatment with ondansetron (0.1 mg kg−1) had no effect on the levels of dopamine, 5‐HT or their metabolites, but in rats given DiMe‐C7, ondansetron significantly inhibited the increase in DOPAC levels in the nucleus accumbens. These results are in agreement with the proposed facilitatory role of 5‐HT3 receptor activation on mesolimbic dopaminergic transmission, and suggest that 5‐HT3 antagonists may have important therapeutic indications for the treatment of CNS disorders in which mesolimbic dopamine systems are perturbed.This publication has 29 references indexed in Scilit:
- Activation of a 5-HT3 receptor releases dopamine from rat striatal sliceEuropean Journal of Pharmacology, 1988
- Zacopride, a potent 5-HT3 antagonistJournal of Pharmacy and Pharmacology, 1988
- Identification and distribution of 5-HT3 receptors in rat brain using radioligand bindingNature, 1987
- Behavioural effects of tachykinins and related peptidesBrain Research, 1986
- Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental areaBrain Research, 1986
- Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugsNature, 1985
- The behavioural effects of a novel substance P analogue following infusion into the ventral tegmental area or substantia nigra of rat brainBrain Research, 1982
- Substance P Analog, DiMe-C7: Evidence for Stability in Rat Brain and Prolonged Central ActionsScience, 1982
- Increased spontaneous activity following substance P infusion into A10 dopaminergic areaNature, 1978
- Catecholamine innervation of the basal forebrain IV. Topography of the dopamine projection to the basal forebrain and neostriatumJournal of Comparative Neurology, 1978